Loading...
XNAS
PACB
Market cap721mUSD
Dec 05, Last price  
2.39USD
1D
-5.16%
1Q
88.19%
Jan 2017
-37.11%
IPO
-85.92%
Name

Pacific Biosciences of California Inc

Chart & Performance

D1W1MN
XNAS:PACB chart
P/E
P/S
4.69
EPS
Div Yield, %
Shrs. gr., 5y
13.58%
Rev. gr., 5y
11.12%
Revenues
154m
-23.19%
2,163,000901,000135,0001,674,00033,863,00025,983,00028,181,00060,594,00092,782,00090,714,00093,468,00078,626,00090,891,00078,893,000130,513,000128,304,000200,521,000154,014,000
Net income
-310m
L+1.02%
-21,518,000-43,754,000-87,703,000-140,166,000-109,388,000-94,465,000-79,293,000-66,160,000-31,696,000-74,375,000-92,189,000-102,562,000-77,819,00029,403,000-181,223,000-296,930,000-306,735,000-309,851,000
CFO
-206m
L-20.49%
-16,732,000-38,303,000-74,838,000-121,996,000-102,974,000-76,822,000-29,833,000-51,468,000-47,889,000-67,929,000-67,518,000-66,430,000-78,312,00019,503,000-111,180,000-263,211,000-259,173,000-206,058,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
IPO date
Oct 27, 2010
Employees
769
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT